The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda
 
Ignacio Melero
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Bayer; Bristol-Myers Squibb; Genentech; Lilly; Lilly; Roche; Roche
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Genentech; Roche
 
Willeke Ros
No Relationships to Disclose
 
Guillem Argiles
No Relationships to Disclose
 
Aurelien Marabelle
No Relationships to Disclose
 
Maria E. Rodriguez-Ruiz
No Relationships to Disclose
 
Joan Albanell
Consulting or Advisory Role - Amgen; Pfizer; Roche
Speakers' Bureau - Amgen; Roche
Travel, Accommodations, Expenses - Amgen; Roche
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
Other Relationship - Pierre Fabre
 
Victor Moreno
No Relationships to Disclose
 
James M. Cleary
Honoraria - Agios
Research Funding - Merck
Travel, Accommodations, Expenses - Roche
 
Joseph Paul Eder
Honoraria - Merck; Nektar
Research Funding - AstraZeneca (Inst)
 
Vaios Karanikas
Employment - Roche
 
Said Bouseida
Employment - Roche
Stock and Other Ownership Interests - Sanofi
 
Federico Sandoval
Employment - Roche
 
Daniel Sabanes
Employment - Roche
 
Sasha Sreckovic
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)
 
Luis G. Paz-Ares
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Roche
 
Jose M. Saro Suarez
Employment - Roche
 
Neil Howard Segal
Honoraria - MedImmune
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Calithera Biosciences; Imugene; Kyocera; Macrogenics; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Pfizer; Roche/Genentech